Sox2 expression in brain tumors: A reflection of the neuroglial differentiation pathway

American Journal of Surgical Pathology

Volumn 32, Issue 1, 2008, Pages 103-112

  Phi, Ji Hoon ^a,b   Park, Sung Hye ^a,b   Kim, Seung Ki ^a,b   Paek, Sun Ha ^a,b   Kim, Jin Hyun ^a,b   Lee, Yun Jin ^a,b   Cho, Byung Kyu ^a,b   Park, Chul Kee ^a,b   Lee, Do Hun ^a,b   Wang, Kyu Chang ^a,b  

^a Seoul National University   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

Brain tumor stem cell; Glial differentiation; Neuroepithelial tumor; Neuronal differentiation; Sox2

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; TRANSCRIPTION FACTOR SOX2; TUMOR MARKER;

ARTICLE; BRAIN TUMOR; CELL LINEAGE; CELL PROLIFERATION; CONTROLLED STUDY; EPENDYMA CELL; GLIA; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MACROGLIA; MAJOR CLINICAL STUDY; MEDULLOBLASTOMA; NERVE CELL DIFFERENTIATION; NEURAL STEM CELL; NEUROECTODERM TUMOR; OLIGODENDROGLIA; PINEAL BODY TUMOR; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BRAIN; BRAIN NEOPLASMS; CELL DIFFERENTIATION; CELL LINEAGE; FLUORESCENT ANTIBODY TECHNIQUE; GLIAL FIBRILLARY ACIDIC PROTEIN; HMGB PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; NEUROGLIA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 37549068145     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31812f6ba6     Document Type: Article

References (24)

1. Bailey OT. Genesis of the Percival Bailey-Cushing classification of gliomas. Pediatr Neurosci. 1985;12:261-265.
2. Bani-Yaghoub M, Tremblay RG, Lei JX, et al. Role of Sox2 in the development of the mouse neocortex. Dev Biol. 2006;295:52-66.
3. Boyer LA, Lee TI, Cole MF, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell. 2005;122:947-956.
4. Bylund M, Andersson E, Novitch BG, et al. Vertebrate neurogenesis is counteracted by Sox1-3 activity. Nat Neurosci. 2003;6:1162-1168.
5. Ellis P, Fagan BM, Magness ST, et al. SOX2, a persistent marker for multipotential neural stem cells derived from embryonic stem cells, the embryo or the adult. Dev Neurosci. 2004;26:148-165.
6. Fan X, Mikolaenko I, Elhassan I, et al. Notch1 and notch2 have opposite effects on embryonal brain tumor growth. Cancer Res. 2004; 64:7787-7793.
7. Ferguson S, Lesniak MS. Percival Bailey and the classification of brain tumors. Neurosurg Focus. 2005;18:e7.
8. Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol. 2006;7:813-820.
9. Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004;64:7011-7021.
10. Gershon TR, Oppenheimer O, Chin SS, et al. Temporally regulated neural crest transcription factors distinguish neuroectodermal tumors of varying malignancy and differentiation. Neoplasia. 2005;7: 575-584.
11. Gessi M, Giangaspero F, Pietsch T. Atypical teratoid/rhabdoid tumors and choroid plexus tumors: when genetics "surprise" pathology. Brain Pathol. 2003;13:409-414.
12. Graham V, Khudyakov J, Ellis P, et al. SOX2 functions to maintain neural progenitor identity. Neuron. 2003;39:749-765.
13. Hemmati HD, Nakano I, Lazareff JA, et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA. 2003;100:15178- 15183.
14. Hong TS, Mehta MP, Boyett JM, et al. Patterns of failure in supratentorial primitive neuroectodermal tumors treated in Children's Cancer Group Study 921, a phase III combined modality study. Int J Radiat Oncol Biol Phys. 2004;60:204-213.
15. Inda MM, Perot C, Guillaud-Bataille M, et al. Genetic heterogeneity in supratentorial and infratentorial primitive neuroectodermal tumours of the central nervous system. Histopathology. 2005;47:631-637.
16. Kunschner LJ. Harvey Cushing and medulloblastoma. Arch Neurol. 2002;59:642-645.
17. Morrison SJ, Perez SE, Qiao Z, et al. Transient Notch activation initiates an irreversible switch from neurogenesis to gliogenesis by neural crest stem cells. Cell. 2000;101:499-510.
18. Piccirillo SG, Reynolds BA, Zanetti N, et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature. 2006;444:761-765.
19. Pomeroy SL, Tamayo P, Gaasenbeek M, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. 2002;415:436-442.
20. Reddy AT, Janss AJ, Phillips PC, et al. Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation, and chemotherapy. Cancer. 2000;88:2189-2193.
21. Sanai N, Alvarez-Buylla A, Berger MS. Neural stem cells and the origin of gliomas. N Engl J Med. 2005;353:811-822.
22. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63:5821-5828.
23. Tanigaki K, Nogaki F, Takahashi J, et al. Notch1 and Notch3 instructively restrict bFGF-responsive multipotent neural progenitor cells to an astroglial fate. Neuron. 2001;29: 45-55.
24. Tong CY, Ng HK, Pang JC, et al. Central neurocytomas are genetically distinct from oligodendrogliomas and neuroblastomas. Histopathology. 2000;37:160-165.